Evidence supporting the use of: Digitalis
For the health condition: Mitral Valve
Synopsis
Source of validity: Scientific
Rating (out of 5): 3
Digitalis (commonly known as digoxin, derived from the foxglove plant) has been historically and scientifically used in the management of heart conditions, particularly in cases involving heart failure and certain arrhythmias. Its use in patients with mitral valve disease—especially mitral stenosis and mitral regurgitation—stems from its positive inotropic effect (increasing the force of cardiac contraction) and its ability to slow the heart rate, particularly in atrial fibrillation, which is a common complication of mitral valve disease.
There is scientific validation for the use of Digitalis in treating symptoms associated with mitral valve disease when these symptoms are complicated by heart failure or atrial fibrillation. Digitalis does not treat the valve abnormality itself, but helps control ventricular rate and improves cardiac output, thereby alleviating symptoms such as dyspnea and fatigue. Numerous clinical guidelines (including those from the American Heart Association and European Society of Cardiology) recommend digoxin as adjunctive therapy in patients with atrial fibrillation and heart failure, which often co-exist with mitral valve disorders.
However, the evidence base is stronger for its use in symptom management rather than as a disease-modifying agent. Its use should be individualized, as newer agents are often preferred, but Digitalis remains a scientifically validated option, especially in resource-limited settings or when other medications are contraindicated.
Other health conditions supported by Digitalis
ArrhythmiaCardiovascular Disease
Congestive Heart Failure
Heart (weakness)
Heart Fibrillation or Palpitations
Mitral Valve
Tachycardia